Patent ID: 9289509
Filing Date: 2016-03-22
CPC Classification: A61K,A61P,B82Y

Claim Text:
1. A method for treating a subject with cancer having target cells expressing CD138, wherein said subject has a refractory disease phenotype, comprising: (i) identifying said subject as not responding, or responding poorly, to treatment with one or more cytotoxic agents, and (ii) administering to said subject that does not respond, or responds poorly, to treatment with one or more cytotoxic agents an effective amount of an immunoconjugate comprising at least one targeting antibody targeting CD138 expressing cells, and at least one maytansinoid effector molecule, wherein said targeting antibody is functionally attached to said effector molecule to form said immunoconjugate, wherein said immunoconjugate is BT062 or has a light chain having at least about 70% sequence identity with SEQ ID No: 2 and a heavy chain having at least about 70% sequence identity with SEQ ID No: 1, wherein said immunoconjugate comprises residues 24-34 (CDR1), residues 50-56 (CDR2) and residues 89-97 (CDR3) of SEQ ID NO: 2 as well as residues 31-35 (CDR1), residues 51-68 (CDR2) and residues 99-111(CDR3) of SEQ ID No:1.